'김갑성' 기자의 전체기사
-
Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozel
- 김갑성 기자
- 2025-07-22 16:02
-
METiS Technologies Showcases AI-Powered Nanodelivery…
HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs). Founded in 1978, the Controlled Releas
- 김갑성 기자
- 2025-07-22 15:52
-
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast T…
SHANGHAI, July 22, 2025 -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. &
- 김갑성 기자
- 2025-07-22 10:25
-
Precision Era to Redefine Treatment, Drive $450B Economic Inv…
SINGAPORE, July 22, 2025 -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp of a Cure' White Paper examines Asia Pacific's readiness for the Precision Era – the current, transformative period where generically prescribed and regularly administered treatments are increasingly giving way to potentially curative therapies tailored to individuals and their disease. Treatments called pre
- 김갑성 기자
- 2025-07-22 10:07
-
OMRON Healthcare Singapore partners with bolttech and QBE…
The comprehensive subscription programme offers OMRON customers in Singapore access to personalised health protection and insights SINGAPORE, July 22, 2025 -- Global insurtech bolttech and OMRON Healthcare Singapore, a global leader in innovative medical equipment for health monitoring and therapy, today announced the launch of their Premium Care subscription plan in Singapore. This three-in-one premium subscription programme offers registered OMRON connect members personalised health insights, protection and exclusive services tailored to OMRON device owners. Underwritten by
- 김갑성 기자
- 2025-07-22 09:30
-
CPHI & PMEC 선전 2025: 아시아와 그레이터 베이 지역에 새로운 기회 창출
[ 메디채널 김갑성 기자 ] 상하이 2025년 7월 22일 -- CPHI & PMEC 차이나 2025(CPHI & PMEC China 2025) 가 6월에 막을 내리며 총 109056명의 역대 최다 참관객을 기록, 중국 제약 산업의 강력한 수요를 다시 한번 입증했다. 이러한 성공을 바탕으로 CPHI & PMEC 선전 2025(CPHI & PMEC Shenzhen 2025)가 2025년 9월 1일부터 3일까지 선전 컨벤션 및 전시 센터(Shenzhen Convention & Exhibition Center, SZCEC)에서 개최된다. 이번 행사는 중국 남부의 주요 제약 시장에 대한 접근 수요 증가에 대응하기 위해 마련됐다. 광둥-홍콩-마카오 그레이터 베이 지역(Guangdong-Hong Kong-Macau Greater Bay Area)의 핵심 관문인 선전은 제약 혁신의 중심지로 부상하고 있다. 이 지역의 헬스 산업 GDP는 2028년까지 2조 위안을 넘어서고 2030년에는 2조 5천억~3조 위안에 이를 것으로 전망되며, 이로 인해 성장과 협업 기회가 전례 없이 확대될 것으로 예상
- 김갑성 기자
- 2025-07-22 08:26
-
2025 Inaugural Global Chest Wall Surgery Conference Conclu…
GUANGZHOU, China, July 21, 2025 -- The inaugural Global Chest Wall Surgery Conference concluded successfully in Guangzhou on July 19, uniting leading medical experts worldwide to share cutting-edge surgical innovations and clinical insights in chest wall surgery. The conference featured a series of high-level academic lectures focusing on the latest developments, advanced techniques, emerging trends, and key issues in chest wall surgery. 9 distinguished medical experts from the United States, India, Japan, Malaysia, Armenia, Thailand, and China delivered keynote speeches, attracting ne
- 김갑성 기자
- 2025-07-21 22:33
-
ICWS Successfully Concludes 2nd Global Program on Cutting…
GUANGZHOU, China, July 21, 2025 -- The 2nd "Latest Chest Wall Surgery Technique Global Training Program", hosted by the Institute of Chest Wall Surgery (ICWS) of Guangdong Second Provincial General Hospital, was successfully held from July 16 to 18, 2025. The program brought together 10 thoracic surgeons from the United States, Romania, India, Armenia, Pakistan, Malaysia, Mexico, and other countries. Participants engaged in comprehensive training on the latest diagnostic methods and surgical techniques in chest wall surgery. A highlight was the innovative surgical appr
- 김갑성 기자
- 2025-07-21 22:32
-
Minaris Advanced Therapies Welcomes Orla Cloak as Chief…
PHILADELPHIA, July 21, 2025 -- Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President an
- 김갑성 기자
- 2025-07-21 21:00
-
Bloomage Achieves FDA GMP Audit with Zero-Deficiency, Reinfo…
PARSIPPANY, N.J., July 21, 2025 -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has announced it successfully passed the U.S. Food and Drug Administration (FDA)'s on-site GMP audit with a "No Action Indicated" (NAI) result. This is the best possible result, confirming complete compliance with no objectionable conditions ("zero-deficiency"). The FDA's issuance of a Current Good Manufacturing Practice (CGMP) compliance notification and Establishment Inspection Report (EIR) formally recognizes Bloomage's pharmaceutical quality
- 김갑성 기자
- 2025-07-21 21:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-21_THU
2025-08-20_WED
- Global Times: Development opportunities, potential and advantages should be better used 23:58
- First IPO Under GIFT City's IFSC Regime - DRHP Filed; Executive Education Platform Leads the Charge 22:19
- Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning 22:14
- TGE alongside with AMTD Obtain Successful Court Decisions against Unauthorised and Infringing Activities in Austria 21:55
- Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year 21:41
- FOSSIL AND 2025-2026 GLOBAL BRAND AMBASSADOR NICK JONAS RELEASE EXCLUSIVE "MACHINE LUXE" CAPSULE 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 21일 06시 40분